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Background: Rheumatoid arthritis (RA) causes painful joint inflammation and is incurable, 
but treatments control RA. Drug regimens are complex, and patients often do not take their 
medication as expected. Poor medication adherence can lead to poorly controlled disease and 
worse patient outcomes. Biologics treatments are expensive and require full engagement from 
patients. We have previously shown that patients from Black ethnic minority backgrounds 
do not fully engage into treatment plan. This study explored the patients’ experiences in and 
satisfaction toward receiving information about biologics and future support preferences in 
South Asian patients with RA.
Methods: Twenty South Asian patients with RA from Royal Wolverhampton Hospitals NHS 
Trust and Central Manchester University Hospitals NHS Foundation Trust participated in 
individual semistructured interviews. Interviews were transcribed and data were analyzed by 
using thematic analysis approach.
Results: Four overarching themes describe the patients’ experience in and satisfaction toward 
receiving information on biologics: 1) current provision of information regarding the “biologics 
journey” and understanding of RA: in this theme, non-English-speaking patients expressed 
heightened anxiety about stepping up to biologics; 2) experience and perceptions of biologics: 
many patients were positive about the biologic experience; however, there were patient-perceived 
delays in getting on to the biologics; 3) factors influencing willingness to try biologics: in this 
theme, a number of factors were identified including seeking advice from doctors abroad; and 
4) recommendations on the desired information to fully understand the use of biologics: some 
patients valued group discussions, while others suggested receiving RA and biologic informa-
tion through a video interaction.
Conclusion: This novel study provides insight into South Asian RA patients’ experiences in 
and satisfaction toward receiving information about biologics. South Asian patients with RA 
reported a range of perceptions about biologics and support preferences, many of which may 
not be shared with the non-South Asian population.
Keywords: rheumatoid arthritis, biologic treatment, patient perceptions, illness beliefs, ethnicity
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovitis 
and associated joint destruction.1 RA causes progressive decline in functional ability 
and limits participation in social and work-related activities.2 RA is also associated 
with an increased risk of cardiovascular diseases (CVDs),3 which are worse among 
South Asian patients4 making inflammation control even more important in this patient 
group. While curative therapies are not currently available, early treatments with 
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disease-modifying antirheumatic drugs (DMARDs) and bio-
logical agents improve joint function,1 work productivity,5 
and health-related quality of life.6 Despite these treatments, 
many patients fail to achieve optimal disease control; 
this is in part due to nonadherence.7 Nonadherence has 
been reported to be a particular problem in South Asian 
patients with RA.8
Our previous work has shown concerns about treatments 
and poor medication adherence to be correlated with illness 
perceptions and cultural beliefs. Moreover, it is known that 
patients from South Asian backgrounds might discontinue RA 
treatments sooner compared with non-South Asian patients.9 
It is only recently found that the provision of appropriate rheu-
matology care services for minority ethnic groups has begun 
to be substantively explored.8,10–12 As the needs of particular 
minority ethnic groups become clearer, questions relating 
to the nature and scope of rheumatology care services have 
moved to the forefront of the minority ethnic group health 
care agenda. Since treating people with RA often involves 
using expensive therapies, it is surprising that there is only 
limited research available which considers the information 
needs of South Asian patients with RA taking biologics. The 
European League Against Rheumatism (EULAR) task force 
recommends guidelines for patient education in inflamma-
tory arthritis.13 These recommendations clearly direct health 
professionals to move toward delivering tailored informa-
tion and to meet the needs of individuals. However, tailored 
information for patients from ethnic backgrounds is limited 
in rheumatology. This study contributes to addressing this 
for one of the UK’s largest minority ethnic populations. This 
study aims at exploring the perceptions of South Asians with 
RA in two prominent geographic areas on their experiences in 
and satisfaction toward receiving information about biologics 
and future support preferences.
Materials and methods
Ethical approval for this study was granted by the North West 
Greater Manchester South Research Ethics Committee (refer-
ence 17/NW/0135), and all patients gave written informed 
consent.
The term “South Asian” here applies to people originating 
from the Indian subcontinent. Patients originating from the 
South Asian continent with a clinician-reported RA diagno-
sis were invited to participate in individual face-to-face and 
telephone interviews.
Patients were purposely sampled from secondary care 
rheumatology outpatient biologic clinics, giving a broad spec-
trum of age, disease duration, and gender. Two recruitment 
sites were used: Central Manchester University Hospitals 
National Health Service (NHS) Foundation Trust and the 
Royal Wolverhampton NHS Trust. Patients were approached 
by the researcher (KK). Patient information sheet was pro-
vided outlining the aim of the study with those who had 
expressed an interest in taking part. A convenient time was 
organized with 20 patients for individual interviews. A topic 
guide was developed for the interview based on discussion 
with patient research partners and the study team (Figure 1). 
This was used to facilitate discussion in the individual 
interviews. These followed an iterative process, with new 
concepts emerging during data analysis being explored in 
subsequent interviews. A pro forma was designed to capture 
demographic data (Table 1).
Interviews were conducted at two hospitals, and eight 
patients were interviewed over the telephone for their conve-
nience. The interviews were undertaken by KK who is fluent 
in English, Hindi, and Punjabi languages. Nine patients chose 
to be interviewed in Punjabi. Recruitment and interviewing 
continued until data saturation had been reached.
All interviews were digitally audiotaped, with interviews 
lasting up to 1 hour. Interviews were transcribed verbatim 
by an independent transcribing company. The transcripts in 
Punjabi were transcribed into English directly from audio-
tapes. A sample of transcriptions was independently checked 
for emerging themes by KK, RS, CM, and SR.14 Data were 
analyzed using thematic approach,15 in which initial analyti-
cal summaries of the interviews were coded line by line; the 
coding framework was discussed by the researchers, and 
coding categories that lacked concordance were absorbed 
back into the coding framework. The initial codes were 
then grouped into the most frequently occurring categories. 
Thematic analysis identified four themes that allowed the 
exploration of patients’ experience about biologics and their 
expectations toward information, and future suggestions 
were also discussed.
Results
Twenty patients with RA participated in the study with an 
age range of 42–67 years. Disease duration ranged from 2 to 
19 years. Of the 20 patients, three were male (refer Table 1 
for complete demographic details).
current provision of information 
regarding biologics journey and 
understanding of rA
Patients rated the quality of information delivered by 
health professional if they viewed that there was an 
opportunity to improve the quality of life (Q1; Table 2). 
The non-English-speaking patients expressed heightened 
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Patients’ experiences in receiving information about biologics
Figure 1 Topic guide used to facilitate interview discussions.
Abbreviations: DMArDs, disease-modifying antirheumatic drugs; rA, rheumatoid arthritis.
1. Experience of RA and DMARDs
What is your perception of having RA?
How many different medicines have you taken?
What happened after you took these medicines?
2. Experience of biologics
Tell me about your experience of taking biologics?
How was the information given?
What information were you given by your nurse?
What information were you given by your doctor?
What information did you seek out yourself? 
What information did other people give you about treatment?
Was the way we gave information about biologics appealing to you at that stage?
In what ways did information about your medicines influence your decision to taking biologics?
Did information ever make you want to stop taking your medicines, if so please describe what happened?
What thoughts were going through your mind when we stepped you up to this treatment?
Did you feel it was explained properly?
Did you know why the step-up occurred?
3. Views on future content for biologics
If we were to develop further material for future patients what would you advise to be the key points and information 
in that?
What ways do you think we should give patients information about medicines? What ways do you most like to receive 
health-related information?
What are your thoughts on medicines information being given to you in a standardized audio manner/format?
What could clinicians and GPs do to encourage patients to get a better understanding of these medicines?
Table 1 Demographic data of the patients interviewed
Gender Level of  
education
Age Employment  
status
Disease duration  
(years)
Current medication
Patient 1 (female) Primary 54 retired 10 DMArDs, steroids, and biologic agents
Patient 2 (female) University 45 retired due to rA 2 DMArDs and biologic agents
Patient 3 (female) secondary 53 Factory worker 5 DMArDs and biologic agents
Patient 4 (female) University 51 Pharmacy technician 4 DMArDs and biologic agents
Patient 5 (female) secondary 42 nursery teacher 10 DMArDs and biologic agents
Patient 6 (female) Primary 59 homemaker 12 DMArDs and biologic agents
Patient 7 (female) secondary 60 retired due to rA 19 DMArDs and biologic agents
Patient 8 (female) Primary 62 homemaker 18 DMArDs and biologic agents
Patient 9 (female) secondary 55 Factory worker 9 DMArDs and biologic agents
Patient 10 (female) Primary 67 retired due to rA 7 DMArDs and biologic agents
Patient 11 (male) secondary 50 Manager 6 DMArDs and biologic agents
Patient 12 (male) secondary 52 Security officer 9 DMArDs, steroids, and biologic agents
Patient 13 (female) University 51 lawyer 7 DMArDs, steroids, and biologic agents
Patient 14 (female) Primary 53 homemaker 12 DMArDs, steroids, and biologic agents
Patient 15 (female) secondary 64 retired due to rA 14 DMArDs, steroids, and biologic agents
Patient 16 (female) secondary 52 Manager 5 DMArDs and biologic agents
Patient 17 (male) secondary 49 Factory worker 19 DMArDs, steroids, and biologic agents
Patient 18 (female) University 47 Manager 5 DMArDs and biologic agents
Patient 19 (female) secondary 54 Teacher assistance 8 DMArDs and biologic agents
Patient 20 (female) Primary 51 Factory worker 7 DMArDs and biologic agents
Abbreviations: DMArDs, disease-modifying antirheumatic drugs; rA, rheumatoid arthritis.
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anxieties of stepping up of treatment and lack of familiarity 
with the process of switching to biologics (Q2; Table 2). 
There was some apprehension about health professional’s 
explanation of biologics; patients often measured this by 
their experience using DMARDs and the length of time it 
took to commence biologics (Q3; Table 2). This notion was 
found in both English-speaking and non-English-speaking 
patients. Many patients expressed a lack of understanding of 
RA; this appeared largely among the non-English-speaking 
patients (Q4; Table 2). Example quote Q1:
I had suffered so much and when they suggested this new 
medication [Enbrel] I just jumped to the chance of getting 
better than I was. My doctor told me all about how this 
medication was really helping many patients to get better 
so I thought why not give it a go. [male English-speaking 
patient]
experiences and perceptions on biologics
There were a mixture of experiences in and perceptions on 
the use of biologics. Many patients viewed the biologics to be 
transforming their life (Q5; Table 3), which motivated them 
to engage with treatment plan (Q6; Table 3). Patients felt that 
the biologics were working better to control symptoms than 
DMARDs (Q7; Table 3). The perceptions on DMARDs and 
the poor efficacy of DMARDs to control symptoms masked 
the positive aspects of biologics for some patients (Q8; 
Table 3). For example, in some patients where there was a 
prolonged use of DMARDs (Q9; Table 3) and with many 
patients who questioned why the treatment was not available 
in the early stages of their disease (Q10; Table 3). Some 
viewed this time framework as “delay” or “time wasting” 
(Q11; Table 3). These perceptions led some patients to 
disengage with treatment plan and have less faith in health 
care professionals in controlling their RA (Q12; Table 3). 
Furthermore, the lack of doubt was displayed in the way that 
doctors in the Western countries managed their medicines 
for some; this was linked to their preference for doctors in 
India (Q13; Table 3). The notion of biologics being delayed 
in treatment journey was expressed by both English-speaking 
and non-English-speaking patients.
Table 3 Quotes (Q) relating to experiences and perceptions of biologics
Q5: i was so much pain free and thought this was fantastic. i had my life back. [female english-speaking patient]
Q6: […] To look at me now there is nothing wrong with me i am just a normal person. i can do everything in the day you know. [female english-
speaking patient]
Q7: i do feel better with this drip now than the other medicines i tried. [female Punjabi-speaking patient]
Q8: i have tried so many things now i just don’t know whether this new drug will work. i just keep thinking the others didn’t so it is matter of 
waiting to see how well this will control the pain. [male Punjabi-speaking patient]
Q9: i don’t [know] why i wasn’t given these a lot sooner why wait so long i know they were saying my markers were low but my life was really 
disrupted by it all. [female english-speaking patient]
Q10: i do really think this all should [have] come sooner. i just couldn’t understand why i had to wait three years. [male Punjabi-speaking patient]
Q11: if you ask me this has been all waste of time. i wasn’t responding to any medications so why was there a long delay? [female Punjabi-
speaking patient]
Q12: it is very frustrating because i don’t think the rheumatologist really understand what we as patients go through. After a while you just give 
up with them. [female english-speaking patient]
Q13: Well I was thinking if the first medicines didn’t work that’s why they are trying another one which I thought would. I had to go to India and 
speak to my doctor over there who told me these medicines would make me worse. [female hindi-speaking patient]
Notes: The interviews were undertaken by KK, who is fluent in English, Hindi, and Punjabi languages. All interviews were digitally audiotaped. Interviews were transcribed 
verbatim by an independent transcribing company. nine patients chose to be interviewed in Punjabi. The transcripts in Punjabi were translated and transcribed into english 
directly from the audio tapes.
Table 2 Quotes (Q) relating to current provision of information regarding biologics journey and understanding of rheumatoid arthritis
Q1: i had suffered so much and when they suggested this new medication [enbrel] i just jumped to the chance of getting better than i was. 
My doctor told me all about how this medication was really helping many patients to get better so i thought why not give it a go. [male english-
speaking patient]
Q2: When i look back at how many they have tried i didn’t think anything would work and the side effects of these were worse than the others. 
[female non-english-speaking patient]
Q3: Well it takes three months to take effect you think right after three months something will happen then you discover about six months 
down the line nothing is happening then you change to another then another. When you go back to the rheumatology department they just try 
another one you do wonder if they know what they know what they are doing. [female english-speaking patient]
Q4: i have been through so many treatments i must say that i still don’t understand why some of the treatments are not working … if i am 
honest i don’t understand the arthritis they say it’s different in my knees than my hands. [female non-english-speaking patient]
Notes: The interviews were undertaken by KK, who is fluent in English, Hindi, and Punjabi languages. All interviews were digitally audiotaped. Interviews were transcribed 
verbatim by an independent transcribing company.
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Patients’ experiences in receiving information about biologics
Example quote Q5: I was so much pain free and thought 
this was fantastic. I had my life back. [female English-
speaking patient]
Factors influencing willingness to try 
biologics
The influencing factors varied and were part of decision 
making when considering biologics. However, it tended not 
to lead to a systematic search for scientific explanations, 
but rather to a reflection on personal experience and the 
experiences of family/relatives. Lay sources of information 
were frequently cited as a major influence on behavior. 
Patients expressed the need for better symptom control, 
and in some cases, patients anticipated biologics to cure 
the condition (Q14; Table 4). Given the degree of severity 
of their RA, some patients felt desperate to try new therapy 
(Q15; Table 4). Higher expectations were found to be 
influenced by information from sources such as clinicians, 
family members, and consultation with overseas doctors or 
by accessing the Internet. Some patients were satisfied with 
the explanation offered for stepping up therapy (Q16; Table 
4); however, this was typically still validated with a fam-
ily member for reassurance (Q17; Table 4). Furthermore, 
patients had explored the Internet and social media to get 
a general view on biologics. Many had used rheumatology 
charity sources for reassurances such as Arthritis Research 
UK (Q18; Table 4), but were generally less familiar with 
National Rheumatoid Arthritis Society (Q19; Table 4). It is 
clear from this fact that some patients may not be familiar 
with different sources of information. Arguably, this could 
reduce their chances of self-management.
The non-English-speaking patients who knew little about 
the biologics and appeared to not want information from the 
UK doctors and nurses sought advice from doctors abroad 
(Q20; Table 4). The information on patient self-management 
and the advice from overseas doctors may be more satisfactory 
for patients; however, it may not be evidence-based or in the 
best interest of preventing the long-term consequence of RA. 
Non-English-speaking patients’ discussions with doctors 
abroad particularly took place in India. Often these doctors 
were found to be family members. The need for these discus-
sions was based on the fact that they felt they knew very little 
about biologics and feared the side effect profile (Q21; Table 4). 
In some of the non-English-speaking patients, the validation 
process from doctors abroad and family members helped them 
to decide whether biologics should or should not to be taken 
(Q22; Table 4). There were a few patients who decided to 
avoid biologics mainly due to the side effect profile and were 
Table 4 Quotes (Q) relating to factors influencing willingness to try biologics
Q14: every time they tried a different medication i kept on thinking right this one will cure me. however, that didn’t happen you know. but now i 
have accepted that this will not be cured it doesn’t matter how hard they try. [female english-speaking patient]
Q15: i was just thinking i want my career back and for me to being [be] a mum again. i was really lonely with other medications because they 
didn’t do anything for me i felt lifeless but with this it was really great. i got back to work. [female english-speaking patient]
Q16: i had enough information plus i had looked up things myself. [male english-speaking patient]
Q17: if it wasn’t for my family members i wouldn’t have been able to make a decision on this medication. [female english-speaking patient]
Q18: i did look at Arthritis research UK for more information. That i found useful but i hadn’t heard of national rheumatoid Arthritis society. 
[male english-speaking patient]
Q19: i must say i haven’t heard of national rheumatoid Arthritis society. i used social media to hear patient stories on tocilizumab. [female 
english-speaking patient]
Q20: i couldn’t really understand why i was now going to take the injections. it did worry me. Yes, so, i did ask the doctor in india also my son 
said “mum don’t take it until we ask the doctors over there” so when he told me that this was very serious medicines, i didn’t feel it was for me. 
[female non-english-speaking patient]
Q21: i am concerned about the side effects but what i can do? i have no other choice. The doctors in india said the look if you can’t function 
then you have to take it. My children also said mum you have to have it that’s the only way now to get better. [female non-english-speaking 
patient]
Q22: i will not take the medicine from here (UK) i am only taking the remedies given to me by the doctor in india. [female non-english-speaking 
patient]
Q23: I did look up at some herbal stuff and my husband wanted me to try them first. But soon I realised these were not going to do anything for 
me. The swelling was there i wasn’t getting any better. [female non-english-speaking patient]
Q24: i did try the ayurvedic medicines. This did help at the start. i thought the swelling had gone down but this only lasted for a short time. [male 
english-speaking patient]
Q25: There are so many side effects to this [humira] i don’t think it is safe to take them. [female non-english-speaking patient]
Q26: i talked to my doctor in india and he gives the advice. [female non-english-speaking]
Notes: The interviews were undertaken by KK, who is fluent in English, Hindi, and Punjabi languages. All interviews were digitally audiotaped. Interviews were transcribed 
verbatim by an independent transcribing company.
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taking herbal remedies suggested by the doctors abroad and/
or by family members (Q23; Table 4). Both English-speaking 
and non-English-speaking patients had tried herbal remedies 
at some point in their journey. However, patients who did 
not achieve full symptom control reverted to biologics and 
did stop taking the herbal remedies (Q24 and Q25; Table 4). 
A few of the non-English-speaking patients did not view the 
use of biologics to be safe and desired to continue with the 
advice offered by doctors in India (Q26; Table 4). This might 
be related to the fact that the patients had more trust in the 
doctors abroad and felt comfortable with the advice given.
Example quote Q14: Every time they tried a different 
medication I kept on thinking right this one will cure me 
but that didn’t happen you know but now I have accepted 
that this will not be cured it doesn’t matter how hard they 
try. [female English-speaking patient]
recommendations on the desired 
information needed to fully understand 
the use of biologics
Patients made recommendations for the future provision of 
information for biologics. There was a considerable variation 
in patients’ understanding of the use of biologics and about 
RA in general (Q27; Table 5). Knowing information about 
their RA and the fluctuant nature of their disease influenced 
the way in which some patients managed their expectation 
of treatment plans (Q28; Table 5). While some patients were 
Table 5 Quotes (Q) relating to recommendations on the desired information to fully understand the use of biologics
Q27: There are lot of us who still don’t understand what rA is. if the other medications [referring to DMArDs] didn’t work then what to say 
these would? [female non-english-speaking patient]
Q28: I have to go with the flow really. Some days are good and some are not. RA does this so I have to take a day at a time really that’s all you 
can do. [female english-speaking patient]
Q29: While you are trying so many medicines, you start thinking will i ever get better. You need that hope and motivation really. [female english-
speaking patient]
Q30: group discussions would be good to hear what others have found being on these medications. sharing that experience would really help us 
because you do start to feel as if you are the only one suffering with this disease. [female english-speaking patient]
Q31: if i had a something like a video to watch then my thoughts on my treatments would be different. You can should developed something like 
where you can see the person talking on this topic. [female non-english-speaking patient]
Q32: When i go out and start talking to my friends i hear more than i have in the department. You start feeling very lonely with this condition it 
will never go away so i think it would help to have something that we can view and listen to and feel more comfortable and think look i am not 
the only one with it. [female english-speaking patient]
Q33: i think it is really important to say that it is treatable i know we can’t cure it so it can be controlled – that you are not alone in this – err 
and it is important to say it is continued treatable condition that the journey goes on. You need to say having the treatments gives you better life 
and how we can weigh up the side effects with benefits. In terms of the disease you don’t have to suffer, I think there is great deal of perception it 
is seen as old person disease so you have to take that thought away. [female english-speaking patient]
Q34: in a lot of the Asian women there is the concept that it is what is it they start believing that they have to suffer. But in fact they can do 
something about it. Oldness is has changed now. if we want medicines to work we have to be part of that plan. so we have to get involved. 
[female english-speaking patient]
Q35: i think it should start from what this problem is about where it comes from, why it is better one day and not others, how we can help 
ourselves like one hand there is medication but what else can be done. [female non-english-speaking patient]
Q36: if i am honest one thing i couldn’t understand why etanercept took so long to mention. i think if the doctors know these medications are 
coming in line why not explain this plan to patients. i think that would help having the feelings of non-hope. it is luck sometimes of which ones will 
work but the action plan should be discussed. [male patient english-speaking]
Q37: it is good to know that future research is still going on because that gives us hope you are trying for us and that would help us to get 
involved. [female non-english-speaking patient]
Q38: When I was first diagnosed I thought this could be cured but as time went on that didn’t happen so you need to tell people what treatment 
does so that we can manage those expectations. [female english-speaking patient]
Q39: it is no good telling me after two years that there are still treatment options why don’t you discuss everything at the start so that i can see 
what you are working with otherwise, my perception is rheumatologist don’t know what they are doing. [female english-speaking patient]
Q40: My gP is good i know that he took his time at the beginning but he gets all the letters from here and he reads them every time i go he will 
ask me how i am getting on. so they are important. [female english-speaking patient]
Q41: The hospitals are busy so therefore i do hope that because my bloods at the gP practice and get my prescriptions from there. i do hope 
that i can get consistency with the gP let’s see. i think better networking and better iT system between the two settings would enable us to work 
with both gP and hospital side. [male english-speaking patient]
Q42: i hardly see my consultant maybe every 12 months it would be nice to discuss things with gP between this time periods. [female english-
speaking patient]
Notes: The interviews were undertaken by KK, who is fluent in English, Hindi, and Punjabi languages. All interviews were digitally audiotaped. Interviews were transcribed 
verbatim by an independent transcribing company.
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[referring to DMARDs] didn’t work then what to say these 
would? [female non-English-speaking patient]
Discussion
To our knowledge, this is the first qualitative study to have 
explored the perspectives of South Asians taking biologics 
and their satisfaction with information regarding biologics. 
In this study, we have identified interweaving factors that 
appeared to influence the experience of biologics. Many 
patients found biologics to be effective and were pleased 
with the results they produced despite their concerns of 
the long-term side effects. However, patients felt that there 
was a low level of satisfaction of biologic information. The 
impact of this appeared to be more on non-English-speaking 
patients. Indeed, this study has highlighted various issues 
and considerations that appear to have particular salience for 
South Asian patients with RA. The majority of South Asian 
patients had been living in the UK for most of their lives; 
the cultural and social practices of their countries of origin 
continued strongly to influence their decision for taking bio-
logics. Family was the most essential source of support for 
South Asians in terms of both providing emotional support 
and assisting patients with decisions regarding biologics. For 
patients with RA from South Asian community, their condi-
tion is probably best understood within the context of their 
families or health professionals from their own background. 
If UK health care recommendations are not consistent with 
the belief systems of families and others, it is likely that those 
recommendations will not be followed. Moreover, this could 
lead South Asian patients to be at an increased risk of failing 
treatment target paradigm.16
An overriding concern expressed in all patients was the 
lack of available information relating to RA and the stages 
of treatment plan. The patients expressed a keen desire for 
this information to be made available mainly via video and/
or through interactive group discussion. The lack of available 
information is resulting in ignorance and fear of conventional 
medicines leading many patients to seek advice on tradi-
tional medicines from doctors or other practitioners abroad. 
Informed education, therefore, is clearly essential to influ-
ence how people manage RA and their expectations toward 
a treatment plan. Some of the themes reported in our study 
were similar to other work exploring biologic information.17 
For example, in those studies, patients were also found to be 
concerned about long-term effects of biologics.18 Moreover, 
the patients were similar in their views about having received 
biologics at a later stage in their journey.19 However, the 
new and fundamental pattern in our study was the constant 
validation of biologics with family members and seeking 
equipped with the relevant information and advice needed 
to make decisions, others lacked motivation and appropriate 
support to engage with RA management and treatment plan 
admitting, resulting in poor medication adherence and pro-
longed symptom control (Q29; Table 5). Some patients valued 
group discussions and suggested sharing good and negative 
experiences about biologics (Q30; Table 5), endorsing this 
to help reduce anxieties. Many of the patients suggested 
receiving RA and biologic information through a video inter-
action (Q31; Table 5) to help reduce the feelings of fear and 
isolation during their illness, thereby minimizing the burden 
of RA (Q32; Table 5). The video interaction may prove 
particularly beneficial for those with language barriers who 
may have inability to understand leaflets. Patients mentioned 
that having clips discussing the experiences of side effects, 
risk–benefit weighting, and emotional issues would all be 
highly valued (Q33; Table 5). This was suggested to be most 
useful for Asian women who might link RA to cultural bar-
riers and view RA to be old persons’ disease (Q34; Table 5). 
Most commented on the usefulness of having information 
in sections; for example, patients suggested an explanation 
on what is RA using pictorial diagrams, and they further 
proposed to know more on how and why RA causes fluctu-
ant patterns (Q35; Table 5). Some suggested that they would 
value listening to how treatments work to control symptoms. 
Patients expressed to know more on why there is a delay in 
trying biologics in their RA journey (Q36; Table 5). Better 
information on the governing body on biologics such as the 
National Institute for Health and Care Excellence may help 
reduce the frustration regarding delays in trying biologics. 
Many suggested knowing the positives of the research tak-
ing place in RA and future goals (Q37; Table 5). There was 
a mention of expectations of treatments being too high with 
many suggesting that the initial DMARDs would control/
cure symptoms (Q38; Table 5). If structured information on 
RA was presented within early stages, then this would help 
patients manage their expectations and recognize the differ-
ent levels of treatment plan (Q39; Table 5). Transparency in 
receiving information between secondary and primary care 
health care professionals was also noted to be paramount 
(Q40; Table 5). The synergy between rheumatology com-
munity and the general practitioners could play an active 
role in disseminating information on RA treatments (Q41 
and Q42; Table 5) since many patients experienced a lack 
of contact with their hospital doctor and felt that GPs could 
add value to their experience.
Example quote Q27: There are lot of us who still don’t 
understand what RA is and if the other medications 
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advice from doctors abroad. The lack of trust in the UK 
rheumatology clinicians could be detrimental to the long-term 
disease management and medication adherence. In addition, 
we found that lack of knowledge of RA was often found to 
impact on treatment decisions and, importantly, patients’ 
view on the opportunity to be cured rather than controlled. 
This was not cited in other studies investigating non-South 
Asian patients’ perceptions on biologics.20
As has been noted throughout, many of the findings 
reported in this study were similar to the findings of our pre-
vious research where we reported lack of knowledge of RA 
and influence of illness perceptions resulting in poor medica-
tion adherence.8 Our work also reflects a wider problem that 
health professionals face in providing effective information 
on RA and treatment to minority ethnic populations.8 This 
could also be problematic for rheumatology charities who 
aim at supporting patients with RA. However, patient sug-
gestions made in this study for future support could be an 
opportunity for both health professionals and rheumatol-
ogy charities to work closely with South Asian patients. 
Furthermore, recommendations made by the patients in this 
study align with EULAR guidelines on patient education 
that suggest reflecting on approaches to educating patients 
with RA.13
Lessons can also be learnt from other chronic disease 
areas, such as CVDs, where researchers designed innovative 
interventions to specifically address ethnic minority. For 
example, “Khush Dil” (happy heart)21 is a project aimed at 
delivering education in a culturally acceptable manner. A 
separate culturally adapted lay-led self-management pro-
gramme for Bangladeshi adults with chronic disease found an 
improvement in self-care.22 Moreover, a systematic review of 
educational interventions among the ethnic minority groups 
strongly recommended the involvement of patients and urged 
education interventions to include culturally sensitive com-
ponents for better clinical outcomes.23 Health education that 
concords with people’s “lay treatment and disease views” is 
more likely to lead to changes in behavior than that which 
seems to contradict such models. The video interaction con-
taining patient-centered information may encourage patients 
to take control of RA and decisions about treatment.
Our study had a number of limitations. We recruited 
patients with a range of disease duration; it could be that 
patients in whom there was a longer use of DMARDs could 
have viewed the RA and biologics experience differently 
than those who started biologics sooner. This required an 
in-depth comparison between the two groups. There were a 
limited number of male patients in the study; therefore, their 
perceptions on RA and biologics could have differed from 
the perspectives of female patients.
Conclusion
These novel data focusing on South Asian patients’ experi-
ences in using biologics and their satisfaction toward informa-
tion received suggest that they have a range of experiences 
from being on biologics and a range of recommendations to 
address the issues they experience. The issues identified as 
specific to South Asians suggest that some of these experi-
ences, level of satisfaction with information, and support pref-
erences may not be shared with non-South Asians. Therefore, 
there is a realistic possibility that many South Asian patients 
with RA are not being served by relevant and appropriate 
information that could have an impact on treatment target 
paradigm. The findings may help health professionals to 
understand and build strategies that might assist patients to 
map their journey with RA and treatments more effectively.
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